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ABSTRACT  
Lung cancer constitutes the major mortality in the world and incidence of the disease varies 
considerably among different ethnic population throughout the world. Palliative 
chemotherapy has been a choice in advance Non-Small Cell Lung Cancer NSCLC as it has a 
better result than best supportive care (BSC). The Primary objective of the present study was 
Co morbidity analysis in patients with lung cancer and the secondary objective was to see the 
impact of co morbidity on survival of lung cancer (NSCLC) patients. This was a retrospective 
observational study. This study was carried out in the Department of Oncology at Ahsania 
Mission Cancer Hospital, Mirpur, Dhaka. This study was carried out during the period from 
January 2013 to December 2013 for one year of enrollment with a follow up of 6 months up 
to June 2014 which makes total study period of 18 months.  All patients with an age above 18 
years of both sexes presented with histologically confirmed stage IIIA, IIIB & IV NSCLC 
(Non Small Cell Lung Cancer) were enrolled in the study. Patient‟s data were collected from 
the indoor and outdoor medical records of the AMCH hospital.  After selection, patients were 
divided into comorbid and non comorbid group. Comorbidity was defined by any associated 
disease except for cancer. For the Kaplan Meier survival analysis patients were contacted 
over the phone to see the status (Dead or Alive) on the last day of the study (2014). Total 
number of patients in this study was 100 with median age of 60. The numbers of patients 
suffering from Squamous cell carcinoma is 53 patients whereas that for adenocarcinoma is 47 
patients. 49 patients were at stage IIIA/IIIB and 51patients were at stage IV. In the comorbid 
arm  30% patient have hypertension (HTN) followed by diabetes mellitus (DM) 22% and 
18% patient have both HTN and DM. Non Co morbid arm has median survival of 12.788 
months (95% CI: 7.5 – 18.06) and Co Morbid has 8.0 months (95% CI: 6.81 – 9.18) and the 
difference is statistically Significant (P < 0.05). According to the stratified histology than 
there is a statistically superior survival in Non Co-Morbid Adenocarcinoma 10.42 months  
than Co – Morbid Adenocarcinoma 8.0 months with a P value of 0.05. In stage IIIA/IIIB non 
co-morbid patients have 15.45 months and co-morbid patients have 9.0 months of median 
survival with a non significant difference. Younger patients (below 60 group) have median 
survival of 7.25 and 8.0 months in Non co-morbid and co-morbid group respectively. But 
older Non comorbid patients (above 60 group) the survival time of 14.36 months  was almost 
twice  than that of  Co-morbid patients 7.02 months and the difference is statistically 
significant (P<0.05). 
Patients with Diabetes Mellitus tend to live longer (Median OS 12.0 months 95% CI 2.3 -
21.6) than the patients with Hypertension (Median OS 7.4 months 95% CI 2.0 -12.78). This 
difference in survival is statistically significant (P < 0.05). We have observed that 68% of 
patients were alive less than a year. One year survival was observed in  27% of cases whereas 
two year survival was observed in 5% of overall population. Co-morbid patients had low 
survival months. Among 50 co-morbid patients 39 have survived less than a year, 9 patients 
have survived 1 year and only 2 have survived 2 year. A higher survival rate is observed in 
Non co-morbid patients. One year survival was observed in 18 patients and 2 year survival 
was observed in only 3 patients in Non co-morbid group. 29 Non co-morbid patients were 
found in the group of less than a year survival which indicates a lesser mortality rate than co-
morbid patients. The study revealed that co morbidity is strongly associated with the survival 
of Non Small Cell Lung Cancer patient in Bangladesh. Even co morbid elderly people are in 
greater risk of mortality. 
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Introduction 
Lung cancer ranks among the most common and most lethal malignancies worldwide. In the 
United States, 2006 cancer statistics showed that lung cancer was the second most common 
cancer for both men and women (92,700 or 13% of all cases, and 81,770 or 12% of all cases, 
respectively), but the number-one cancer killer in both sexes (90,330 men, 31% of all cancer-
related deaths; and 72,1300 women, 26% of all cancer-related deaths) 
[1]
. Lung cancer is 
rapidly emerging as a major cause of mortality in the Middle East, Africa, and Asia as well. 
The incidence of lung cancer varies considerably among different ethnic populations 
throughout the world. The global rise in lung cancer incidence, together with the fact that the 
overall 5-year survival of patients with this disease is less than 15%, underscores the 
magnitude of the lung cancer epidemic.  
Carcinoma of lung was the most common cancer among the patients who attended National 
Institute of Cancer Research and Hospital (NICRH), Bangladesh. A total of 3,209 lung cancer 
patients attended during three years (2005-2007), 86% (2,763) of them were males. The 
number of lung cancer patients were increasing year by year; there were 902 lung cancer 
patients in 2005, 1,076 in 2006 and 1,231 in 2007 
[2]
. This again is the only data of the 
hospital and the real situation is probably worse than this. Lung cancer death rates for men 
khave dropped by 19% during the past decade, whereas these rates continued to increase in 
women up to the year 2002. Lung cancer was revealed as the leading cancer among males in 
the medical oncology department of NICRH 
[3]
. 
 
1. Literature Review 
 
1.1.Types of Lung Cancer 
Lung cancer is divided into 2 main types, small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). The category of the cancer determines the treatment options. 
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1.1.1. Small Cell Lung Cancer 
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers 
[4]
 Also known 
as oat cell carcinoma SCLC tends to be aggressive. The cancer often grows rapidly 
and spreads to other regions including lymph nodes, bones, brain, adrenal glands, and the 
liver. Risk of developing SCLC is highly associated with tobacco smoking. Less than 5% of 
patients diagnosed with the disease have never smoked. 
 
1.1.2. Non-Small Cell Lung Cancer 
Non-small cell lung cancer (NSCLC) is divided into three categories, based on appearance 
and other characteristics of the cancerous cells: 
 Squamous cell carcinoma (SCC): SCC accounts for approximately 25-30% of all 
lung cancer cases. SCC is highly associated with tobacco smoking and usually 
develops in the central region of the lungs. 
 Adenocarcinoma: Adenocarcinomas account for approximately 40% of all lung 
cancer cases. This cancer type usually develops in the outer region of the lungs.
 
 
 Large Cell Carcinoma (LCC): LCC accounts for approximately 10-15% of all lung 
cancer cases. LCC is associated with rapid tumor growth and poor prognosis.
 
 
Other, less common types of lung cancers include carcinoid tumors, adenoid cystic 
carcinomas, hamartomas, lymphomas, and sarcomas.
 
 
1.2.Etiology of Lung Cancer 
Smoking is the primary risk factor for the development of lung cancer, accounting for 90% 
cases in men and 70% cases in women 
[5, 6]
.
  
Lung carcinogenesis is known to occur from an 
accumulation of several genetic alterations, most commonly with p53 mutations and deletions 
on chromosomes 3p, 5q, 9p, 11p, and 17p. These alterations are more frequent in smokers 
than in nonsmokers 
[7]
. 
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Industrial agents found in the environment, such as asbestos, coal tar fumes, nickel, 
chromium, arsenic, nickel, diesel exhaus have been related to the development of lung 
cancer. 
Most Non-small cell lung cancers (NSCLCs) are directly attributable to cigarette smoking. A 
variety of occupational and environmental exposures have been implicated in the 
pathogenesis of lung cancer. These include asbestos and silica fibers, organic compounds 
such as chloral methyl ether and Polycyclic Aromatic Hydrocarbon (PAH), diesel fumes and 
air pollution, metals such as chromium and nickel, arsenic, and ionizing radiation. Of 
particular interest in this regard are the effects of fruits and vegetables, as well as 
micronutrients such as retinols, carotenoids, vitamin C. Zinc, copper, and selenium intake 
appears to be associated with reduced lung cancer risk 
[8]
. 
Adenocarcinoma surpassed squamous cell carcinoma as the most common subtype of lung 
cancer in both men and women in the mid-1980s. Adenocarcinoma has been more common 
in women since the 1950s and became the most common lung cancer diagnosis in men in 
1990 
[9]
. Smoking low-tar filter cigarettes may increase the rate of adenocarcinoma because 
these cigarettes have a higher nitrate content, which has been shown to produce 
adenocarcinoma in laboratory animals 
[10–12]
. Among the various histologic types of lung 
cancer, adenocarcinoma has the slowest doubling time and small cell carcinoma has the 
fastest 
[13]
. Lung cancer may spread via hematogenous routes or locally within the 
lymphatics. In most cases, lymph node metastases seem to occur earlier than distant 
hematogenous spread. 
Lung cancer occurs mainly in the elderly. Because of a demographic shift towards an older 
population and improved survival of patients with cardiovascular diseases, more elderly 
people are at risk of developing lung cancer. The proportion of patients aged 70 or older has 
increased from 26% in 1970 to 43% in 2000 
[14]
.With the rising mean age, more patients will 
be diagnosed with one or more other serious diseases at the time of lung cancer diagnosis 
(comorbidity) 
[15-18]
. 
The clinical management of lung cancer is therefore becoming increasingly complex. 
Furthermore, these patients are often excluded from clinical trials. This means that little is 
known about the best way to treat elderly patients with comorbidity and about the outcome of 
treatment such as complications and survival. 
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Through the 1960s, the predominant type of non-small cell carcinoma was squamous cell 
carcinoma. Although the overall incidence of lung cancer has dramatically increased during 
the past 30 years, the relative incidence of squamous cell carcinoma has decreased, and 
adenocarcinoma has become the dominant cell type, a phenomenon that has been temporally 
associated with the changes in tobacco blends and the use of filters in cigarettes.
 
Adenocarcinomas are most often located in the periphery of the lung radio graphically, and in 
the smaller airways histologically. Therefore, they are not readily amenable to detection by 
sputum or other types of cytology, at least in their early stages, but become apparent in the 
relatively translucent pulmonary periphery on computed tomography (CT) scan in earliest 
stages and then on chest x-ray. 
An important distinction is made between SCLC and NSCLC since these treatments are 
different. The choice of treatment is based on histology, general condition and extent of 
disease. The management of lung cancer should be based on histo-pathological type. NSCLC 
represents one treatment group and SCLC another 
[4]
. For non-small cell lung cancer 
(NSCLC) the choice is between radical surgery, radical or palliative radiotherapy. The 
primary curative treatment for NSCLC is surgery. In stage I and stage II a complete surgical 
resection is almost always possible 
[4]
. 
NSCLC is one of the most chemo resistant solid lesions with a response rate of 15-25% for 
single agent usually of 3-5 months duration. However, when combining two or three of the 
most active drugs the response rate increases to 30-50%, mainly due to new more active and 
less toxic cytotoxic agents, such as Taxanes, Vinorelbine and Gemcitabine. Commonly used 
regimens in NSCLC are Cisplatin-Paclitaxel, Cisplatin-Gemcitabine, Carboplatinum-
Gemcitabine, Cisplatin-Vinorelbine, Carboplatinum-Paclitaxel and Docetaxel-Cisplatin 
 
1.3 Epidemiology 
Smoking is the main, although not the only, etiologic factor of lung cancer. An estimated 5%- 
20% of lung cancers arise in association with exposure to respiratory carcinogens, including 
asbestos. Only an estimated 10% of heavy smokers develop lung cancer. An estimated 20% 
of lung cancers arise in non-smokers and only 20% of these can be attributed to passive 
smoking 
[61]
. 
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Notably, diet has been proposed to be one of these factors and the usual aspects (fruits and 
vegetables) have been proposed to have a protective effect against the development of lung 
cancer in both smokers and non-smokers. This effect has been linked to a protective effect 
against mutations by nutrients. 
From 1973 to 1994, a much larger increase in the incidence of lung cancer was observed for 
women than for men. Whether this increase suggests a higher gender-related risk of cancer 
for women merely reflects changing smoking patterns remains controversial. The overall 
increase in incidence of adenocarcinoma that has occurred since the 1960s has been 
correlated with the introduction of filter tips in cigarettes. 
 
Different histological types of lung cancer have different associations with cigarette smoking 
and this association is the highest for squamous cell carcinoma (SqCC) and small cell 
carcinoma (SCC). Human papillomavirus (HPV) infection is an etiologic factor in the rare 
cases of SqCC of the lung that arise in the setting of laryngeal papillomatosis. HPV, 
including high risk serotype, has been detected in approximately 20% of patients with lung 
cancers; whether it constitutes a cofactor in the development of such cancer outside the 
setting of laryngeal papillomatosis, however, is not clear. 
 
1.4. Natural History  
It is often difficult to determine the site of origin of lung cancer. Garland et al. studied 463 
patients, 150 of whom had less advanced tumors that were suitable for determination of the 
site of origin: 58% of these tumors originated in the right lung and 42% in the left lung. Once 
established, tumors are likely to grow with a constant doubling time, at least during the early 
stages of their development. Among the various histologic types of lung cancer, 
adenocarcinoma has the slowest doubling time and small cell carcinoma has the fastest. 
Efforts to detect lung cancers in earlier stages through screening programs have been 
unsuccessful. Screening programs funded by the National Cancer Institute (NCI) in the 1970s 
failed to justify screening with serial chest x-rays and sputum cytology. These studies 
demonstrated that although many cancers could be diagnosed at earlier stages, no 
6 
 
improvement in overall survival was shown for screens at intervals less than 1 year. Thus, an 
annual chest x-ray remains the current recommendation for screening 
[62]
. 
Imaging technologies have improved during the past two decades. With the deficiencies of 
the previously mentioned studies in mind, lung cancer screening was revisited by the Early 
Lung Cancer Detection Project, Henschke et al. reported a trial of 1,000 patients at high risk 
(age older than 60 years, at least 10 pack-years of cigarette smoking, and no prior cancers) for 
development of lung cancer who underwent baseline and annual repeat low-dose computed 
tomography (CT) and chest radiography 
[62]
. 
Noncalcified nodules were detected in 27% of the patients. Malignant disease was detected in 
2.7% by CT and in 0.7% by chest radiography. Of the 27 detected cancers, 26 were 
resectable. The NCI-sponsored National Lung Screening Trial is now conducting a 
randomized controlled trial to test whether low-dose CT scanning can reduce lung cancer 
mortality in asymptomatic individuals. Subjects are randomly selected to undergo screening 
with low-dose CT or chest x-ray. The National Lung Screening Trial will enroll 50,000 high-
risk heavy smokers (and former heavy smokers who quit within 15 years before 
randomization), age 55 to 74 years. Participants will undergo an initial screening and two 
subsequent annual screenings and will be observed for a minimum of 4.5 years. Final 
analyses are expected in 2009 
[62]
. 
 
1.5. Risk Factors of lung cancer 
1.5.1.  Diet 
Observations in the 1970s showed that lung cancer patients had low levels of vitamin A 
which prompted intense interest in the potential role of diet in modulating lung cancer risk. 
Subsequent studies suggested that by inhibiting DNA damage, anti-oxidant micronutrients 
might reduce lung cancer risk 
[60]
. 
Data regarding fruit and vegetables consumption and lung cancer risk are somewhat 
contradictory. CS protective effect of fruit consumption has been suggested in some but not 
all studies. On the other hand majority of studies performed to date indicate that increased 
vegetable consumption diminishes lung cancer risk and particularly carrots and tomatoes 
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appear to have a protective effect. Specific vegetables which can reduce lung cancer risk have 
not been defined yet 
[60]
. Overall, the data pertaining to the impact of vitamins and 
micronutrients and lung cancer risk are inconclusive.  
 
1.5.2. Etiology 
A variety of agents have been proven to be carcinogenic in humans 
[63]
. Tobacco smoke is the 
dominant agent and represents a complex mixture of physical and chemical carcinogens. 
There is direct relationship between the amount of tobacco exposure and risk of developing 
lung cancer.  
The type of cigarette seems to also influence the risk; i.e. a filter actually decreases the risk. 
Stopping smoking is associated with a gradual decrease in the risk, but a long period of time 
(more than 6 years) is necessary before an appreciable diminution of risk occurs. 
Interestingly, in Asians, the proportion of cases attributable to active smoking may not be a 
high. Asbestos exposure is associated with the development of mesothelioma and also 
bronchogenic carcinoma. The risk from asbestos is particularly more pronounced when 
combined with cigarette smoking.  
Atmospheric pollution has been indicated as a causative agent because the higher the 
incidence of lung cancer in urban than rural areas. A more direct relationship has been shown 
in cases of pitchblende miners who are involved with radioactive ores. Metals, mostly nickel 
and silver, but also chromium, cadmium, beryllium, cobalt, selenium and  steel have been 
proven to be carcinogenic in animals and are occupational hazards, particularly when 
combined with other factors.  Chemical products such as chloromethyl ethers have been 
associated with the development of lung cancer, especially small cell lung cancer (SCLC). 
 
1.5.3. Genetic Disposition 
Whereas the vast majority of lung cancers are attributable to cigarette smoking, fewer than 
20% of smokers develop this disease. Although observations suggest a genetic disposition to 
lung cancer, to date, the genes conferring susceptibility to this disease remain elusive. Tumor 
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suppressor gene abnormalities are more common in small cell lung cancer and dominant 
oncogene expression is more frequent in non-small cell lung cancer (NSCLC). 
Approximately three fourths of lung cancer is non-small cell carcinoma, which include 
squamous cell carcinoma, adenocarcinoma and broncho-alveolar carcinoma. Small cell 
carcinoma is a distinct disease of neuro-ectodermal origin and clinically aggressive tumor 
biologic process. 
Surgical resection is the preferred treatment for NSCLC in clinical stage I and II disease. If 
surgical margins yield positive findings, post-operative radiation therapy is considered to 
reduce the possibility of local failure. Mediastinal irradiation is commonly recommended for 
patients with completely resected stage II disease. Medically inoperable disease in patients 
with early stage NSCLC is treated with radiation therapy. 
For patients with clinically evident N2 disease, induction chemotherapy followed by radiation 
therapy is a common treatment.  Neo-adjuvant chemo-radiation therapy remains 
investigational. Sequential or con-current chemotherapy and radiation therapy has increased 
survival in patients with stage III NSCLC in comparison with patients treated with radiation 
therapy 
[60]
. 
1.6. Early Detection 
The major problem in the treatment of lung cancer has been that patient at the time of 
symptoms, and thus diagnosis, usually have had advanced stage disease.  This has 
encouraged researchers to setup screening programs to detect the disease in more localized 
stages. Screening programs using chest radiographs and sputum cytology have been 
disappointing, since these tests were not able to decrease mortality from lung cancer 
[62]
. 
 
1.7. Symptoms of Lung Cancer 
A. Symptoms of lung Cancer related to local tumor growth  
I. Due to central tumor growth 
 Cough 
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 Wheeze or stridor 
 Postobstructive pneumonia(fever productive cough) 
 Dyspnea with obstructive pattern on testing 
 Hemoptysis 
 Poorly localized, dull pain 
II. Due to peripheral tumor growth 
 Pleuritis or chest pain 
 Dyspnea with restrictive pattern on testing 
 Pleural effusion 
 Cough 
B. Symptoms of lung cancer due to Regional Spread 
I. Nerve entrapment Syndromes 
 Hoarner‟s Syndrome (enopthalmos, meiosis, ptosis), cervical sympathetic 
nerves 
 Diaphragmatic paralysis- phrenic nerve 
 Hoarness- recurrent laryngeal nerve on the left 
 Ulcer pain with vasomotor changes- 8th cervical and 1st thoracic nerve 
II. Vascular involvement 
 Venous distension and swelling of the face, neck, upper chest 
 Superior vene cava 
 Temponade, heart failure, arrhythmia- pericardial involvement 
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II. Direct Invasion 
 Dysphagea- esophageal compression or invasion 
 Dyspnea, stridor- due to tracheal involvement 
 Dyspnea due to pleural effusion 
 Broncho-esophageal fistula 
C. Lung Cancer Symptoms due to metastatic disease 
I. Central Nervous system- Brain 
 Headache and change in pattern of chronic headache 
 Unexplained nausea/ vomiting 
 Blurred vision 
 Diplopia 
 Confusion or change in mentality 
 Focal weakness 
 Seizures- jacksonian or grand mal 
 Ataxia 
II. Central Nervous system- spinal cord 
 Back pain localizing over the spine 
 Rodicular back pain 
 Ataxia 
 Bowel or bladder dysfunction 
 Paraparesis or paraplegia 
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 Sensory loss- parasthesia or loss of position or sense 
III. Central Nervous System- leptomeninges 
 Change in mental state 
 Isolated cranial nerve dysfunction 
 Non-dermatomal pain syndrome 
 Headache 
 Visceral disturbances 
 Nausea/ vomiting 
 Bowel or bladder dysfunction 
IV. Bone 
 Back pain 
 Long bone pain 
 Rib pain 
 Pathological fractures 
V. Liver 
 Right upper quadrant fullness/ pain 
 Early satiety 
 Hectic fevers with no infections etiology 
VI. Adrenal gland 
 Flank pain 
 Adrenal hypofunction (Addison‟s disease- rare) 
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VII. Other sites 
 GI Tract- nausea/ vomiting; epigastric pain 
 Skin- subcutaneous nodules; breast masses 
 Choroid- blurred vision 
D. Common Paraneoplastic Syndrome associate with lung cancer 
I. Endocrine 
 Hypocalcaemia (ectopic PTH) 
 Cushing‟s Syndrome (ectopic ACTH) 
 SIADH (ectopic anti-diuretic hormone) 
 Carcinoid syndrome (ectopic serotonin) 
 Gynecomastia (ectopic beta-HcG) 
II. Neurologic 
 Eaton-Lamber Syndrome 
 Optic neuritis 
 Subadequate cerebellum degeneration 
 Progressive multifocal leuko-encaphalopathy 
 Autonomic neuropathy 
III. Musculoskeletal 
 Polymyositis 
 Clubbing 
 Pulmonary hypertrophic osteoarthropathy 
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IV. Hematologic 
 Anemia of chronic disease 
 Leukemoid reactions 
 Thrombocytosis 
 Hypercoagulative state (Trousseau‟s Syndrome, Marantic endocarditis or DIC) 
V. Cutaneous 
 Dermatomyositis 
 Hyperkeratosis 
 Acanthosis negricans 
 Hyperpigmentation 
VI. Miscellaneous 
 Nephrotic syndrome 
 Anorexia/ cachexia 
 Vasoactive intestinal peptide secretion with severe diarrhea 
 
E. Common Clinical Presentation of lung cancer 
 Asymptomatic pulmonary nodule 
 Change in “smoker‟s cough” 
 Non-purulent pneumonia in an adult 
 Persistent upper respiratory infection 
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 Hemoptysis 
 Hoarseness 
 Signs and symptoms of metastatic disease 
 Signs and symptoms of a paraneoplastic syndrome 
 Carcinoma of unknown primary site 
 
1.8. Diagnosis of Lung Cancer  
Patients presenting with the above symptoms mentioned in Section 5.7.3 require a chest X-
ray. A lateral view may be helpful, a computed tomography (CT) Scan of the chest and upper 
abdomen is recommended before bronchoscopy as peripheral tumors will not be reached by 
bronchoscopy and in these cases, a CT guided biopsy is required for histopathological 
diagnosis. Magnetic resonance imaging (MRI) can be used to determine if there are direct 
invasion structures contraindicating surgery but is not superior to CT in detecting mediastinal 
disease.  
 
1.8.1 PET scanning 
Positron Emission Tomography (PET scanning) is not currently widely used in the diagnosis 
and follows up of patient with lung cancer. PET scanning is a high resolution, whole body 
technique which can demonstrate the extent of tumor spread. It is also useful in 
differentiating between benign and malignant pulmonary nodules. PET Scan detects lymph 
node spread more accurately than even spiral CT Scan.  
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1.9. Comorbidity 
Comorbidity is the occurrence of concomitant disease in addition to an index disease of 
interest or the simultaneous occurrence of multiple diseases in an individual. 
Comorbidity has an inherent influence on each patient‟s initial treatment and the treatment 
effectiveness of patient care. Previous studies have demonstrated that less aggressive 
treatment is given to patients with breast cancer, prostate cancer, lymphoma, or lung cancer 
who have specific existing comorbidities 
[19-24]
. Several diseases such as hypertension, 
ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease 
(COPD), and diabetes mellitus (DM) are considered to have a significant influence on the 
survival of cancer patients 
[20, 25-28]
. 
In the case of lung cancer patients, pulmonary and cardiovascular function may have a 
significant impact on survival 
[20, 29-32]
. Elderly patients with Stage I or II lung cancer are less 
likely to receive surgery than younger patients 
[31]
. Patients with COPD, cardiovascular 
disease, or DM comorbidity also have a lower resection rate. Morbidity and mortality of non-
small cell lung cancer (NSCLC) patients following resection are associated with poor 
pulmonary function or cardiovascular disease 
[20]
. Older NSCLC patients have a higher 
prevalence of comorbid cardiovascular disease or COPD, which may cause additional 
morbidity and reduce their survival. NSCLC patients with comorbidity have a two-fold 
increased risk of death compared with patients without comorbidity 
[29]
. 
The presence of multiple comorbid diseases is common among lung cancer patients, with 
22.1% of patients having five or more comorbid diseases, 54.3% having three or more, and 
88.3% having one or more 
[32-34]
. Tuberculosis (TB), COPD, and DM are the most common 
comorbidities associated with a reduced survival among patients with lung cancer 
[32]
. It was 
also identified that comorbidity is important for predicting the survival of both localized and 
advanced lung cancer 
[34]
. 
The symptoms of lung cancer can be masked by the symptoms of comorbid diseases such as 
chronic bronchitis, COPD, TB, DM, hypertension (HT), or even heart disease 
[33,35,36]
. 
Patients with comorbid diseases may ignore symptoms or delay reporting them to a 
physician, because the symptoms of lung cancer are often confused with those of comorbid 
diseases. Comorbid diseases may exert direct effects on the host immune system and reduce 
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the duration of survival, and are thus among the most important factors for determining lung 
cancer survival 
[37, 38]
. 
Lung cancer is associated with age and smoking, and both age 
[39, 40]
 and smoking 
[41, 42]
 are 
strongly associated with comorbidity. Thus, it is expected that comorbidity has an important 
impact in lung cancer patients, yet to date comorbidity has not been well studied in this 
population. The common perception that most lung cancers are rapidly progressive and, as a 
consequence, almost all lung cancer patients die from their disease 
[43]
 may explain why the 
study of comorbidity in lung cancer patients has received restricted attention 
[59]
. 
Co Morbidity 
Diabetes Mellitus 
Hypertension 
Bronchial asthma 
COPD 
IDH 
HTN & DM 
COPD & HTN 
DM & IDH 
 
 
1.9.1 Lung cancer and COPD 
COPD is a commonly encountered comorbidity in patients with lung cancer 
[44–46]
. Indeed, 
recent studies have shown that COPD affects 50–90% of lung cancer patients [46, 47]. 
Moreover, patients with COPD are three to four times more likely to develop lung cancer 
compared with smokers with normal lung function 
[48, 49]
, and lung cancer is a major cause of 
mortality in COPD patients, particularly in those with mild or moderate disease 
[50]
. However, 
it must be noted, that at least some of the association may be related to „detection bias‟ in that 
subclinical COPD may be diagnosed during pre-assessment for lung surgery or radiotherapy 
in a lung cancer patient 
[51]
. 
 
COPD has long been recognized as an indicator of a high risk of complications after lung 
resection 
[52, 53]
. For example, in patients with lung cancer and COPD who undergo surgery, 
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postoperative pneumonia and tracheostomy are more frequent in patients with COPD than in 
those without 
[54]
. Moreover, the presence of COPD significantly increases the risk of cardiac 
dysrhythmias, specifically supraventricular tachycardia 
[55]
. Mortality rates are significantly 
higher in lung cancer patients who have postoperative pulmonary complications than in those 
who do not 
[52]
, and in comparison with lung cancer patients who do not have COPD, those 
with COPD have poorer long-term survival as a result of respiratory insufficiency 
[56]
, a 
higher rate of recurrence of the lung cancer 
[54]
, and poorer survival after surgery 
[57]
. The 
clear link between the severity of the COPD and survival confirms COPD as a key prognostic 
factor in patients with lung cancer 
[57, 58]
. 
 
1.10. Treatment (Management of Non-Small Cell Lung Cancer/ NSCLC) 
The management of lung cancer should be based on the histopathological type. NSCLC 
represents one treatment group and SCLC represents another. 
 Surgery 
Surgery offers the best chance of cure. Patients must be carefully selected as incomplete 
excision is of no benefit. Patients must undergo extensive staging and, in practice, only those 
with stage I and II tumors and good cardiopulmonary function are suitable for surgery. 
Patients may have surgically resectable disease but are unable to tolerate a surgical procedure 
due to co-morbidity. These patients may be considered for radical radiotherapy. 
In stage I and II NSCLC, a complete surgical resection is almost always possible. The 
procedure of choice is the one that encompasses all existing tumor tissues and provides 
maximum conservation of the lung tissue, as determined by the location and degree of tumor 
involvement including sampling of all mediastinal nodal stations or complete lymph node 
dissection.  Segmented resection will be selected for patient with small, peripheral tumors (≤ 
2cm in diameter), with no evidence of extension or metastases (T1N0M0). Lobectomy is 
performed for patients with centrally located tumor mass within the lobe and an adequate 
tumor free margin is required for this type of resection.  
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Pneumonectomy is the procedure of choice for patients having more extensive disease, with 
tumors extending to the orifice of the lobar bronchus and tumors originating within or 
extending to the main stem bronchus, with involvement of more than one lobe.  
 
 Radical Radiotherapy 
 Thoracic Radiotherapy 
Thoracic radiotherapy is particularly challenging as the tumor is a moving target within as 
area surrounded by critical and radiosensitive tissues, such as lung parenchyma and spinal 
cord. 
 Palliative Radiotherapy 
The volume of a treatment field is determined by the site of the tumor and diseaee extent but 
the dose for palliative treatment was established by a series of more trials published between 
1991 and 1996. The effectiveness of palliative radiotherapy for the common symptoms 
control rates of lung cancer are hemoptysis 52%, cough 52% and pain 57% respectively. 
Bone pain and pathological features are common complications of lung cancer and can be 
controlled by a palliative dose of radiation. Brain metastasis with good performance status 
and controlled extracranial disease should receive whole brain radiotherapy.  
 
 Chemotherapy for Non-Small Cell Lung Cancer 
The quality of life of patients with metastatic NSCLC may be improved by the judicious use 
platinum-based two drug combinations (doublets). A meta-analysis has shown a modest 
increase in survival of 1.5 months with platinum doublets compared to best supportive care. 
 
Doublets of cisplatin with gemcitabine, paclitaxel, docetaxel or vinorelbine give similar 
response rates of 20.3% and a similar median survival of 8-10 months. The average 1 year 
survival is 30-30-40%. The addition of a third drug did not increase response rates or 
survival. 
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A meta-analysis showed cisplatin doublets produced a statistically significant better response 
rate and better survival when compared to carboplatin-based combinations. A combination of 
cisplatin (75mg/m
2
) and the anti-folate drug pemetrexed (500mg/m
2
) given 3 weekly is 
associated with fewer adverse side effects than other combination.  
 
Combined Modality Therapy in Unresectable Stage III disease 
As the effects of radiotherapy and chemotherapy used alone have been very modest, the 
combination of these has been explored extensively in non-resectable and locoregional 
NSCLC. The efficacy of concurrent chemoradiation has been confirmed in several meta-
analysis of randomized trials, showing combined modality therapy to be superior to radiation 
alone, and it is now considered the standard of care for the treatment of locally advanced 
NSCLC.  
 
What still remains to be classified are the optimal volume, dose, schedule and fractionation of 
radiotherapy, issues which are currently under investigation in multi-national trials, including 
identification of the best chemotherapy regimen.  
 
Chemotherapy for Stage IIIb (malignant pleural effusion) and Stage IV disease 
NSCLC is one of the most chemo-resistant solid tumors with a response rate of 15-20% for 
single agents, usually of 3-5 months durations. However, when combining two or three of the 
most active drugs, the response rate increase to 30-50%, mainly due to new more active and 
less toxic cytotoxic agents, such as taxanes, vinorelbine, and gemcitabine. No one regimen 
has been demonstrated to be superior in the first-line treatment for  patients with advanced 
NSCLC.  
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At present, it is generally accepted that platinum-based chemotherapy should be the standard 
first-line treatment of advanced NSCLC patients in good performance status, since 
documented median survival benefit of 2-4 months is achieved and symptom relief is 
documented to occur in 40-60% of all patients. Chemotherapy is usually administered for no 
more than 4-6 cycles in patients with stage IV NSCLC.  
 Results and Prognosis 
The overall survival rate for all patients treated is 5% - 10% with little impact made by 
current diagnostic screening procedures or newer multimodality approach in the common 
adenocarcinoma and SCC. 
 
 Overall Survival 
According to SEER data, the relative 5 year survival rate is 8% to 10%, and the 10 year 
survival rate is 5% to 7%.  For 5 years survivors, there is small rate of attrition; however 65% 
will still be alive at 10 years. The survival rate is somewhat better for female than for male- 
13% versus 10% at 5 years 
[60]
. 
 
 Biological Therapy 
Much interest has focused on new biological agents against NSCLC including: 
 Receptor-target therapy 
 Signal transduction-cell cycle inhibitors 
 Angiogenetic inhibitors 
 Gene therapy 
 Vaccines 
Many of these agents are now in clinical development with most expensive having been 
obtained with the oral, small molecule EGFRtyrosine kinase inhibitors Gefitinib (Tressa 
TM
) 
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and Erlotinib. Of these, Gefitinib has been extensively evaluated in both phase II and III 
trials. As a single agent, gefitinib resulted in response rate of 12-18% and symptom 
improvement is 40-43% lasting from a few weeks to several months at a dose level of 250mg 
or 500mg PO daily with inclusion of 103 and 102 NSCLC patients in the two trials. All 
patients had failed one or more previous chemotherapy regimens. Highest activity was 
observed among patients with adenocarcinoma, especially alveolar cell carcinoma and 
females. Very recent data indicate that clinical responsiveness to gefitinib is related to 
specific mutations in the EGFR gene. 
 
2. Null Hypothesis 
Co-morbidity (side diseases) are not associated with the survival of patients with Non Small 
Cell Lung Cancer. 
 
3. Objectives 
General Objective 
 Analysis of Co morbidities in patients with lung cancer. 
 Specific Objective 
 To assess the impact of co morbidities on survival of Non small cell lung cancer patients 
with standard treatment and care. 
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4. Research Methodology 
Materials and Method 
4.1  Types of Study 
This was a retrospective observational study. 
4.2  Place of study 
This study was carried out in the Department of Oncology at Ahsania Mission Cancer 
Hospital, Mirpur, Dhaka. 
4.3  Period of Study 
This study was carried out during the period from January 2013 to December 2013 for 1 
(one) year for enrollment with a follow up of 6 months up to June 2014 which makes total 
study period of 18 months.  
4.4. Study Population 
All patients with an age above 18 years of both sexes presented with histologically confirmed 
stage IIIA, IIIB & IV NSCLC (Non Small Cell Lung Cancer) were enrolled in the study. 
4.5. Sample Size 
A total of 100 patients were enrolled in the study and they were divided in to two arm. After 
1:1 randomization both arm contains 50 patients and thus sample size was 100.Arm A 
contains non co morbid patients while arm B contains co morbid patients.   
4.5.1. Sample Size Formula 
Sample size was calculated using standard sample size formula which is  
   Z
2
*(P)*(1-P) 
SS = ------------------------------ 
                     C
2
 
Where: 
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Z = Z value 
p = percentage picking a choice, expressed as decimal 
c = confidence interval, expressed as decimal  
Z value is always 1.96 for 95% Confidence level, p is 50% (0.5 when expressed as 
decimals)and c is the confidence interval and it is 8% i.e; margin of accepted error (0.08 in 
decimals). 
So by putting value in the equation we get: 
   (1.96)
2
*(0.5)*(1-0.5) 
SS = ------------------------------ 
                     (0.08)
2 
3.8416 * 0.5 * 0.5 
=     ------------------------------ 
 0.0064 
 
0.9604 
=     ------------------------------ 
 0.0064 
 
= 150.06 
= 150 
 
Our required sample size was 150. 
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4.5.2. Sampling Technique 
Non Probability Quota sampling technique was applied for the study.  
 
4.6. Selection criteria of subjects 
4.6.1. Inclusion Criteria 
 Unresectable or locally advanced histologically or cytologically confirmed NSCLC 
 Male or female ≥ 18 years. 
 At least one evaluable/measurable lesion with no symptomatic or history of untreated 
brain metastases 
 Patients having at least one co morbidity such as diabetes mellitus, hypertension 
COPD etc.  
4.6.2. Exclusion Criteria  
 Patient aged less than 18. 
 Patient with small cell or large cell carcinoma. 
 Patient with no follow-up data. 
 
4.7. Study design 
In this single centered retrospective clinical study, previously recorded data were screened 
and checked for eligible patients. Data were collected only of those patients who were either 
co morbid or non comorbid with Non Small Cell Lung cancer. 
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4.8. Study Procedure 
This was a retrospective observational study between two different group of lung cancer 
patient to compare the response and survival in patients with locally, advanced or metastatic 
NSCLC with Non co-morbidity or Co-morbidity. 
Patient‟s data were collected from the indoor and outdoor medical records of the AMCH 
hospital.  After selection, patients were divided into comorbid and non comorbid group. 
Comorbidity was defined by any associated disease except for cancer. For the Kaplan Meier 
survival analysis patients were contacted over the phone to see the status (Dead or Alive) on 
the last day of the study (2014). 
4.8.1. Steps of the study procedure 
Research Instrument 
 A proforma for the questionnaire and recording of the clinical and laboratory findings. 
 
4.8.2. Statistical analysis 
All data were recorded systematically in preformed data collection form and quantitative data 
was expressed as mean and standard deviation and qualitative data was expressed as 
frequency distribution and percentage. All the statistical analysis was performed by using 
SPSS ( 
Statistical Package for Social Sciences) for windows version 20. 95% CI (Confidence Limit) 
was used, probability (P) value <0.05 was considered as a level of significance. 
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5. RESULT 
5.1. Age distribution: 
Total number of patients in this study was 100 with median 60 and range 57. Maximum 
frequency was 87 and minimum 30. 
5.2. Age group:  
Total number of patients was divided in three groups 20-39, 40-59, 60 and above. In age 
group 20-39 there were only 3 patients while in age group 40-59 there were 38 patients. 
Highest number of patients was in last group about 59 patients. 
 
Fig. 1: Age group distribution 
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5.3. Sex:  
It is seen that maximum number of patients are male about 85as compared to female 15. So 
males are more prone to lung cancer than female. 
 
Fig. 2: Distribution according to sex 
5.4. Histology: 
According to histology the study was divided into two groups squamous cell carcinoma and 
adenocarcinoma.The number of patients suffering from Squamous cell carcinoma are 53 
patients whereas adenocarcinoma includes 47 patients. 
 
Fig. 3: Distribution according to Histology 
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5.5. Stages: 
The study was divided in two stages IIIA/IIIB and IV.49 patients were at stage IIIA/IIIB and 
51patients were at stage IV. 
 
Fig. 4: Distribution according to Stage 
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5.6. Co morbidity 
 
In the comorbid arm maximum (30%) patient were found to have hypertension (HTN) 
followed by diabetes mellitus (DM) (22%), 18% patient were found to have both HTN and 
DM. 
 
Fig. 5: Bar Charts showing distribution of patients with Single Co Morbidity 
 
 
 
Fig. 6: Bar Charts showing distribution of patients with Multiple Co Morbidity 
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5.7. Patient Characteristics  
Patient Characteristics is summarized in the table below. 
Table 1: Characteristics of the study population. 
Categories Co-Morbid Non Co-morbid 
No. Of Patient 50 50 
Median Age 64 60 
Sex 
Male 43 42 
Female 7 8 
Histology 
Squamous Cell Carcinoma 27 26 
Adenocarcinoma 23 24 
Stage 
IIIA / IIIB 26 23 
IV 24 27 
Number of Co Morbidity 
One 32 N/A 
Two 16 N/A 
Three 1 N/A 
Four 1 N/A 
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5.8. Survival Data 
5.8.1. Overall Survival 
Overall Survival was observed superior in non Co morbid arm than Co morbid arm. Non Co 
morbid arm has median survival of 12.788 months (95% CI: 7.5 – 18.06) and Co Morbid has 
8.0 months (95% CI: 6.81 – 9.18) and the difference is statistically Significant (P < 0.05). 
Table 2: Kaplan-Meier median overall survival data 
Co-morbidity 
Median 
Survival in 
Months 
Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Non Co - Morbid 12.788 2.694 7.509 18.067 
Co - Morbid 8.000 .603 6.819 9.181 
Overall 9.000 1.154 6.739 11.261 
 
Table 3: Log Rank (Mantel-Cox) test for significance for OS 
Overall Comparisons 
Test Chi-Square df Sig. 
Log Rank (Mantel-Cox) 4.696 1 .030 
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Fig. 7: Kaplan – Meier curve for overall survival 
 
5.8.2. Survival According to Histology 
 
If the data are stratified according to histology then there is a statistically superior survival in 
non Co-Morbid Adenocarcinoma (10.42, 95% CI: 1.07 – 19.76) than Co – Morbid 
Adenocarcinoma (8.0, 95% CI: 7.02 – 8.97) with a P value of 0.05. 
In Squamous cell carcinoma non Co-morbid patients has median survival of 12.788 months 
(95% CI: 6.21 – 19.36) and Co-Morbid has 7.396 months (95% CI: 4.72 – 10.06). 
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Table 4: Kaplan-Meier median survival data (stratified by Histology) 
Histology Co - morbidity 
Median 
Survival in 
Months 
Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Squamous Cell 
Carcinoma 
Non Co - Morbid 12.788 3.354 6.215 19.361 
Co - Morbid 7.396 1.362 4.726 10.066 
Overall 9.632 2.847 4.051 15.213 
Adenocarcinoma 
Non Co - Morbid 10.421 4.768 1.076 19.766 
Co - Morbid 8.000 .497 7.026 8.974 
Overall 8.000 1.029 5.983 10.017 
Table 5: Log Rank (Mantel-Cox) test for significance on Histology interaction  
Pair wise Comparisons 
Test Histology Co-morbidity 
Non Co - 
Morbid 
Co - Morbid 
Chi-
Square 
Sig. 
Chi-
Square 
Sig. 
Log Rank 
(Mantel-
Cox) 
Squamous Cell 
Carcinoma 
Non Co - Morbid   1.423 .233 
Co - Morbid 1.423 .233   
Adenocarcinoma 
Non Co - Morbid   3.855 .050 
Co - Morbid 3.855 .050   
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Fig. 8: Kaplan – Meier curve for Squamous cell carcinoma 
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Fig. 9: Kaplan – Meier curve for Adenocarcinoma 
 
5.8.3. Survival According to Stage 
In stage IIIA/IIIB non co-morbid patients has 15.45 months and co-morbid has 9.0 months of 
median survival with a non significant P value of 0.12. Little lower results are observed in 
Stage IV, where non co-morbid has a survival of 9.6 months and co-morbid has 7.0 months. 
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Table 6: Kaplan-Meier median survival data stratified by Stage 
Stage Co-morbidity 
Median 
Survival 
in 
Months 
Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
III A / 
IIIB 
Non Co - Morbid 15.450 2.864 9.837 21.063 
Co - Morbid 9.000 .659 7.708 10.292 
Overall 10.000 2.192 5.704 14.296 
IV 
Non Co - Morbid 9.632 2.354 5.017 14.247 
Co - Morbid 7.000 .770 5.491 8.509 
Overall 8.000 1.030 5.981 10.019 
 
Table 7: Log Rank (Mantel-Cox) test for significance (stratified by stage) 
Pair wise Comparisons 
 Stage Co-morbidity 
Non Co - Morbid Co - Morbid 
Chi-
Square 
Sig. 
Chi-
Square 
Sig. 
Log Rank (Mantel-
Cox) 
III A / 
IIIB 
Non Co - 
Morbid 
  2.380 .123 
Co - Morbid 2.380 .123   
IV 
Non Co - 
Morbid 
  3.114 .078 
Co - Morbid 3.114 .078   
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Fig. 10: Kaplan – Meier curve for Stage IIIA/IIIB 
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Fig. 11: Kaplan – Meier curve for Stage IV 
 
5.8.4. Survival According to Age group 
Younger patients (Below 60 group) have median survival of 7.25 and 8.0 months in non co-
morbid and co-morbid group respectively. But older non co-morbid patients (Above 60 
group) has almost twice the survival months (14.36) than Co-morbid patients (7.02) and the 
difference is statistically significant (P<0.05). 
 
 
 
 
39 
 
Table 8: Kaplan-Meier median survival data stratified by Age Group 
Age group Co-morbidity 
Median 
Survival 
in 
Months 
Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
Below 60 
Non Co - Morbid 7.250 3.394 .597 13.903 
Co - Morbid 8.000 .677 6.673 9.327 
Overall 8.000 .926 6.185 9.815 
Above 60 
Non Co - Morbid 14.366 3.088 8.313 20.419 
Co - Morbid 7.021 1.212 4.646 9.396 
Overall 9.632 1.767 6.169 13.095 
 
Table 9: Log Rank (Mantel-Cox) test for significance (stratified by age group) 
Pair wise Comparisons 
Test 
Age 
group 
Co-morbidity 
Non Co - Morbid Co - Morbid 
Chi-
Square 
Sig. 
Chi-
Square 
Sig. 
Log Rank 
(Mantel-Cox) 
Below 60 
Non Co - 
Morbid 
  .144 .704 
Co - Morbid .144 .704   
Above 60 
Non Co - 
Morbid 
  5.117 .024 
Co - Morbid 5.117 .024   
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Fig. 12: Kaplan – Meier curve for Age below 60 group 
 
 
 
 
 
 
 
41 
 
 
 
Fig. 13: Kaplan – Meier curve for Age Above 60 group 
 
 
5.8.5. Survival according to the DM and HTN patient only 
 
Patient with DM (Diabetes Mellitus) tends to live longer (Median OS 12.0 months 95% CI 
2.3 -21.6) than with HTN (Hypertension) Median OS 7.4 months 95% CI 2.0 -12.78. This 
difference in survival is statistically significant (P < 0.05). 
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Table 10: Kaplan-Meier median survival data for DM and HTN patients only 
 
Comorbidity DM , HTN Median 
Estimate Std. Error 95% Confidence Interval 
Lower Bound Upper Bound 
Diabetes Mellitus 12.000 4.947 2.304 21.696 
Hypertension 7.396 2.748 2.009 12.783 
Overall 9.000 1.118 6.808 11.192 
Table 11: Log Rank (Mantel-Cox) test for significance (for DM and HTN only) 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 4.661 1 .031 
 
 
 
Fig. 14: Kaplan – Meier curve for DM and HTN patient only 
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5.9. Survival Rate 
In our study we have observed 68% of patients have lived less than a year. One year survival 
was observed in only 27% of cases whereas two year survival was observed in only 5% of 
overall population. 
Table 12: Survival Rate for the study population 
 
 
Overall 
Populatio
n 
Percentage 
Non Co-
Morbid 
Co-Morbid 
Categories 
Less than a year 68 68.0% 29 (58%) 39 (78%) 
1 year survival 27 27.0% 18 (36%) 9 (18%) 
2 year survival 5 5.0% 3 (6%) 2 (4%) 
Total 100 100.0% 50 (100%) 50 (100%) 
 
 
By analysis of the survival data for non Co-morbid and Co-morbid patients, it is discovered 
that Co-morbid patients have low survival months. Among 50 patients 39 patients has 
survived less than a year, 9 patients has 1 year survival and only 2 patients were in 2 year 
survival group in Co-morbid patients. A higher survival rate is observed in Non co-morbid 
patients. One year survival was observed in 18 patients and 2 year survival was observed in 
only 3 patients in Non co-morbid group. 29 Non co-morbid patients were found in the group 
of less than a year survival which indicates a lesser mortality rate than co-morbid patients. 
 
 
 
 
 
 
The whole survival analysis is summarized in the table 13 
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Table 13: Summarized Survival data for non co-morbid and co-morbid patients 
Category Non Co-morbid Co-Morbid P value 
Survival In 
Months 
Overall 12.79 8.0 0.030* 
Histology 
Squamous Cell 
Carcinoma 
12.78 7.39 0.23 
Adenocarcinoma 10.42 8.00 0.050* 
Stage 
IIIA/IIIB 15.45 9.0 0.12 
IV 9.63 7.0 0.078 
Age group 
Below 60 7.25 8.0 0.70 
Above 60 14.36 7.02 0.024* 
Survival rate 
(%) 
Survival rate (%) 
Less than a year 
survival 
58% 78% N/A 
One year survival 36% 18% N/A 
Two year survival 6% 4% N/A 
Survival of 
Co-morbid 
patient only 
Co-morbidity Median Survival P Value 
DM 12.0 
0.031* 
HTN 7.39 
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6. Discussion 
In this retrospective study sample size was 100. The study was divided into two arm; Non 
Co-Morbid and Co-Morbid arm having 50 patients in each arm. 
In the descriptive study we had 85 (85%) male and 15 (15%) female patients having Non 
Small Cell Lung Cancer (NSCLC). Among them 59 patients were having age 60 and above, 
38 patients had age between 40 to 59 and only 3 patients were found in the age group of 20 to 
39. 
Among 100 NSCLC patients 53 were found with Squamous cell carcinoma histology and 47 
were with Adenocarcinoma histology. 
49 patients were found in the stage IIIA/IIIB and 51 patients were in stage IV (Metastatic). 
Single co morbidity was observed in 70% of patients in co morbid arm where Hypertension 
30%  was most predominant co morbidity, followed by Diabetes mellitus 22%, Bronchial 
asthma 8%, COPD 6% and IDH 4%  respectively. While multiple co morbidity was observed 
in 30% of patients in co morbid arm where Hypertension and diabetes mellitus 18% followed 
by COPD and Hypertension 4%, Diabetes mellitus sand Tb 4%  Dibetes mellitus and IDH 
2%, COPD and bronchial Asthma 2% respectively. 
In the survival analysis non co-morbid arm produces maximum survival (12.79) than co-
morbid arm (8.0). This survival difference was measured by Log Rank (Mantel – Cox) test 
and the result shows a statistically significant P value (0.03) which is one of the prominent 
finding of our study. Sheighet. al. (2012) found a similar relationship in their survival 
analysis [64]. They found that compared to lung cancer patients without tuberculosis, those 
with tuberculosis had a significantly shorter average survival duration (584 days vs. 791 days, 
P = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend 
was observed in lung cancer patients with diabetes [64]. 
Stratified data with histology shows another statistically significant result for the superior 
survival of non co-morbid (10.42) patient having Adenocarcinoma than co-morbid patients 
(8.0). But there is no significant evidence in the survival analysis in squamous histology. 
Non co-morbid patients in both stage IIIA/IIIB and IV tend to have more survival months 
than co-morbid patients in the respective stage. But there is no statistical evidence to prove 
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the difference is significant. Although Sheighet. al. (2012) reported that Survival days 
increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years] days, p = 0.020) 
and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, p<0.001). 
[64]. 
Another important finding of our study is non co-morbid patients having age above 60 are 
likely to have better survival than those of co-morbid patients. Log Rank test shows a P value 
of 0.024 which is highly significant. But those patients in age below 60 are likely to have 
almost similar survival in both non co-morbid and co-morbid arms but there is not enough 
statistical significant evidence. 
In our study we have also found an increase 1 year and 2 year survival percentage in non co-
morbid patients compared to co-morbid patients. We found a one year survival for non 
comorbid was 36% and for co-morbid was 18%. In a Danish cancer registry analysis it was 
found that a decrease in one year survival percentage in co-morbid patient [65]. They have 
reported an increased survival among co-morbid patients 25% to 28% and 33% to 41% for 
non co-morbid patients registered from 2000 to 2011.  So our study shows a similar findings 
with those reported by Danish cancer registry that is the co-morbidity survival in lung cancer 
is decreased compared to non comorbidity cases. 
 
7. Conclusion 
In our study we have seen that co morbidity is strongly associated with the survival of Non 
Small Cell Lung Cancer (NSCLC) patient in Bangladesh. Even co morbid elderly people are 
in great risk of mortality. We have also found a relationship between histology and co 
morbidity. 
8. Limitations 
There are few limitations of this study. And these are as follows: 
 This study was done in a single cancer center. Thus it does not reflect the complete 
scenario in our country. 
 Sample size was small. 
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 We could not establish the relationship between survivals based on chemotherapy or 
treatment pattern as treatment (both chemotherapy and radiotherapy) has an important 
role in survival. So it was an unintentional confounder in our study. 
 
 
9.  Recommendations for Future Study  
In future a multicenter phase III large scale prospective Randomized Clinical Trial (RCT) 
should be performed to evaluate the actual effect of co morbidity on lung cancer survival in 
Bangladesh. 
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Patient Consent Form 
 
I _______________________________________________ hereby give my well informed and 
conscious consent for participation in the study conducted by Asma Aminul Haque, in the oncology 
department, Ahsania Mission Cancer Hospital, Mirpur, Dhaka. This study may bring some precious 
medical information to be useful for me and for human being in future.  
 
I have been informed that written records regarding my illness, treatment and follow up will be kept 
by by the Investigators.  
I am convinced that during participation in the study I will not be exposed to any physical, 
psychological, social or legal risk. The privacy and confidentiality of mine will be secured. I have 
read the above which was fully explained to me and give my informed consent for the study. 
 
 
  
___________________________________                _____________________________                                                                                                
Signature/Thumb impression of the patient         Signature of principle investigator 
Date:               Date: 
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Data collection form for “Association of co morbidities with survival of patients with 
NSCLC” 
 
Name:        Sex: M        F  Age: 
Address:    Thana:   District:  Division: 
Contact Number: 
Diagnosis:         Stage: 
Histology: 
ECOG status:  
Diagnosis date:   Status  Death    Alive Last follow-up date:         Death Date: 
Co morbidity: 
   COPD        CVD Cerebrovascular disease Hypertension DM Others : 
 
Treatment:  RT            CT     RT     CT Surgery   S     CT          S     RT    CT 
Regimen Brand No. of Cycles Progression/switch date 
    
    
    
    
    
    
 
Toxicities 
Anemia  Neutropenia Thrombocytopenia Febrile Neutropenia Fatigue  
Vomiting Allopecia Others 
 
